Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.42 |
| ▸ | MMP2 | P08253 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1392811 | 0.81 | HRH4 (0.51) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL1004793 | 0.81 | HRH4 (0.48) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL13562340 | 0.80 | HRH3 (0.43) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL24851409 | 0.79 | HRH4 (0.50) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL21310107 | 0.79 | HRH4 (0.50) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL22509467 | 0.79 | HRH4 (0.50) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL17575660 | 0.79 | HRH4 (0.50) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL29228916 | 0.78 | ALOX15 (0.41) | ALDH1A1KDM4EHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL31221504 | 0.76 | MAPK1 (0.49) | HRH3ALDH1A1RAB9AKDM4EHPGD | |
| SCHEMBL24374825 | 0.75 | KDM4E (0.42) | HRH3ALDH1A1RAB9AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| EP-4408845-A1 | NOVEL COMPOUNDS | Sitryx Therapeutics Limited (GB) | 2024-08-07 | — | — | EP | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2023052783-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2023-04-06 | — | — | WO | disclosed |
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440830-B2 | Tetrahydro-fused pyridines as histone deacetylase inhibitors | 4SC AG (DE) | 2013-05-14 | — | — | US | disclosed |
| EP-2197552-B1 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2012-11-21 | — | — | EP | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| WO-2009037001-A2 | NOVEL TETRAHYDROFUSEDPYRIDINES AS HISTONE DEACETYLASE INHIBITORS | 4SC AG (DE) | 2009-03-26 | — | — | WO | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| EP-1768979-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| EP-0186431-B1 | ANTI-HYPERTENSIVE OCTAHYDRO-6-AZAINDOLE DIPEPTIDE DERIVATIVES | Pfizer Limited (GB) | 1988-02-03 | — | — | EP | disclosed |
| US-4711882-A | INHIBITOR OF ANGIOTENSIN CONVERTING ENZYME; HYPOTENSIVE AND CARDIOTONIC AGENTS | PFIZER INC. (US) | 1987-12-08 | — | — | US | disclosed |
| EP-0186431-A1 | Anti-hypertensive octahydro-6-azaindole dipeptide derivatives | Pfizer Limited (GB) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | PNPO, NLRP3, CHRM3 | HRH3 743/4885SLC6A2 4134/4885SLC6A4 3293/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | HRH3 3491/4885SLC6A2 4791/4885SLC6A4 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.